JSOT 2024 (Japan Society Of Toxicology)

Fukuoka, Japan

Cell and Gene Therapy Answers: What to know about companion diagnostics development

A companion diagnostic (CDx) is an in vitro diagnostic providing essential information for the safe and effective use of a corresponding therapeutic product. By identifying patients most likely to benefit from or who are at risk of adverse events from a therapy, CDx can help guide decisions for targeted treatment strategies—which is why many regulatory bodies now recommend incorporating CDx within cell and gene therapy (CGT) programs. However, for many developers, questions remain about when CDx are truly needed, how to choose the right CDx partner and the kind of testing required for CDx assays. To gain clarity on CDx strategy and best practices, we spoke with Devin Craven, associate director of regulatory affairs for Labcorp, and Laura Huning, a scientist for Labcorp’s diagnostic development services.

ECHA guidelines

Labcorp Announces New Strategic Service Offerings within Precision Oncology Portfolio

Labcorp® Tissue Complete, a comprehensive genomic profiling service, now available in Geneva and Shanghai to support global clinical trials Company expands leadership in liquid biopsy comprehensive genomic profiling for solid tumors with the integration of OmniSeq® INSIGHT circulating tumor DNA

Solving the puzzle of preeclampsia

Hear from the subject matter experts addressing the prevalence of preeclampsia in the U.S. From early patient education, at-home monitoring and clinical management to digital health intervention and testing for preeclampsia across all pregnancy trimesters—the panelists are shedding light on the work helping to improve pregnancy outcomes and advance health equity.

Unlock the 3 keys to drug discovery success -foresight, hindsight and insight

Translating brilliant science into great medicines is a challenging, lengthy and expensive business. With drug discovery taking almost three years,1 you need a laboratory partner who can enhance your chances of moving from an idea to a lead candidate and then to IND-enabling studies in a cost-effective and timely way.

Spilling the Tea on Biomarkers

You might be asking yourself, “What is the hype about biomarkers?” and “Should I be talking with my healthcare provider about biomarkers?” Well, the answer is yes, you should, and we are here today to help you get started!

Labcorp to Present Multiple Abstracts across Precision Oncology at the 2024 ASCO Annual Meeting

Abstracts offer insights into precision oncology diagnostics for triple-negative breast cancer, liquid biopsy and machine learning for tumor profiling BURLINGTON, N.C. , May 30, 2024 /PRNewswire/ --  Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, will